



Midwest Cardiovascular Research Foundation

Spring 2009

Jesse Stoakes Research Award

2009 Stoakes Student Research

Midwest Cardiovascular Research Foundation, Davenport, announced the 2009 recipients of the Jesse Stoakes Student Research Awards for its 8-week summer session.

Jay Welvaert has completed his junior year at Cornell College, Mount Vernon, Iowa, majoring in biochemistry and molecular biology. Jay has worked as an EMT in the Mount Vernon area, and plans to pursue a career in medicine and medical research.

Raheel Yaseen has completed his junior year at the University of Iowa, Iowa City, majoring in biology in preparation for a medical career. While attending the University of Iowa, Raheel worked for the Center for Diversity & Enrichment as a Supplemental Instruction Leader for Principles of Biology.

The Stoakes Student Research Award was established in 2006 in memory of Jesses Stoakes, son of Penny and David Stoakes of Bettendorf, who had an avid interest in cardiovascular medicine. He died at age 16 of injuries suffered in an automobile accident.

Midwest Cardiovascular Research Foundation was established in 2002 by Nicolas W. Shammass, MD, MS, as a 501(c)(3) non-profit, tax-exempt scientific and educational foundation dedicated to heart health, education and awareness through quality research and professional and community education programs and projects.



| In This Issue... | |
|---|-------------|
| Jesse Stoakes Research 2009 Award..... | 1 |
| Clinical Trials | 2, 3 |
| CIPG 2009 Conference..... | 4 |
| MCRF Abstract..... | 4 |
| Welcoming Dr. Eric Dippel..... | 5 |
| MCRF Publications | 5 |
| MCRF Board of Directors | 6 |
| MCRF Donation Form | 7 |

Clinical Trials


Over 24 clinical trials are currently conducted at MCRF. These include peripheral vascular disease, carotid disease, coronary artery disease, congestive heart failure, hypertension, anticoagulants, NSAIDs and others. The following clinical trials are on-going at MCRF:

- ♥ **ABRAXIS:** A Phase II Trial of ABI-007 (Paclitaxel Albumin-bound Particles) for the Prevention of Restenosis following Revascularization of the Superficial Femoral Artery (SFA)Principal Investigator: Eric Dippel, MD, Clinical Coordinator: Penny Stoakes, RN, Contact Phone Number: 563-324-4384, Sponsor: Spectranetics
- ♥ **BIOGEN:** A randomized, double-blind, placebo-controlled, parallel-group, study to assess the effects of intravenous BG9928 on body weight in subjects with acute decompensated heart failure and renal insufficiency....Principal Investigator: Nicolas W. Shammass, MD, Clinical Coordinator: Lori Christensen, RN, Contact Phone Number: 563-324-4384, Sponsor: Quintiles
- ♥ **CG104 (COGENTUS)** (Closed to enrollment): A randomized, double-dummy, parallel group, phase 3 efficacy and safety study of CGT-2168 compared with clopidogrel to reduce upper gastrointestinal events including bleeding and systematic ulcer disease....Principal Investigator: Nicolas W. Shammass, MD, Clinical Coordinator: Lori Christensen, RN, Contact Phone Number: 563-324-4384, Sponsor: Parexel
- ♥ **COSTAR:** (CLOSED) Currently in follow-up stage. Cobalt chromium STent with Antiproliferative for Restenosis II Trial....CLOSED, Direct Stenting will start in February 2007. Principal Investigator: Nicolas W. Shammass, MD, Clinical Coordinator: Denise Coiner, MS, RTR, Contact Phone Number: 563-324-4384, Sponsor: Conor Medsystems
- ♥ **CRESCENDO:** Comprehensive Rimonabant Evaluation Study of Cardiovascular ENDpoints and Outcomes (CRESCENDO).... Principal Investigator: Eric Dippel, MD, Clinical Coordinator: Penny Stoakes, RN, Contact Phone Number: 563-324-4384, Sponsor: Sanofi-Aventis
- ♥ **CHOICE:** Carotid Stenting For High Surgical Risk Patients; Evaluating Outcomes Through The Collection of Clinical Evidence ("CHOICE")....Principal Investigator: Eric Dippel, MD, Clinical Coordinator: Penny Stoakes RN, Contact Phone Number: 563-324-4384, Sponsor: Abbott Vascular
- ♥ **REDUCE hf:** Implantable Cardioverter Defibrillator....Principal Investigator: Rafat Padaria, MD, Clinical Coordinator: Lisa Decker, RN, BSN, Contact Phone Number: 563-324-4384, Sponsor: Medtronic
- ♥ **CLEARWAY:** Dethrombosis of Lower Extremity Thrombus by Local Delivery of Thrombolysis Using ClearWay Transcatheter Balloon Irrigation: a feasibility and dose finding study....Principal Investigator: Nicolas W. Shammass, MD, Clinical Coordinator: Denise Coiner, MS, RTR, Contact Phone Number: 563-324-4384, Sponsor: Atrium Medical Corporation
- ♥ **CYPHER ELITE:** A Prospective, Single-Blind, Randomized, Multi-Center Study Comparing the CYPHER@ELITE™ to the CY{HER@BxVELOCITY@ Sirolimus-Eluting Stent Systems....Principal Investigator: Eric Dippel, MD, Clinical Coordinator: Desyree Weakley, RN, Contact Phone Number: 563-324-4384, Sponsor: Johnson & Johnson
- ♥ **DEEP EMBOLI:** (CLOSED) This study is currently in follow-up phase. Distal Embolic Event Protection Using Excimer Laser Ablation in Peripheral Vascular Interventions, a pilot registry....Principal Investigator: Nicolas W. Shammass, MD, Clinical Coordinator: Denise Coiner, MS, RTR, Contact Phone Number: 563-324-4384, Sponsor: Spectranetics
- ♥ **EMINENCE:** Evaluation of M118 IN Percutaneous Coronary Intervention. MOM-M118-006 A randomized, multi-center, open-label, parallel group feasibility study to determine the safety and efficacy of the rationally engineered heparin M118 vs. UFH in patients with stable coronary artery disease undergoing percutaneous coronary intervention (PCI)....Principle Investigator: Eric Dippel, MD, Clinical Coordinator: Desyree Weakley, RN, Contact Phone Number: 563-324-4384, Sponsor: Momenta Pharmaceuticals, Inc.
- ♥ **PRECISION:** A Randomized, Double Blind, Parallel-Group Study of Cardiovascular Safety In Osteoarthritis or Rheumatoid Arthritis Patients With or at High Risk for Cardiovascular Disease Comparing Celecoxib With Naproxen and Ibuprofen **THIS IS AN ARTHRITIS STUDY**....Principal Investigator: Nicolas W. Shammass, MD, Clinical Coordinator: Lori Christensen, RN, Contact Phone Number: 563-324-4384, Sponsor: Pfizer
- ♥ **PERSEUS** (Closed to enrollment): A Prospective Evaluation in a Randomized Trial of the Safety and Efficacy of the Use of the TAXUS® Element™ Paclitaxel-Eluting Coronary Stent System for the Treatment of De Novo Coronary Artery Lesions...Principal Investigator: Eric Dippel, MD, Clinical Coordinator: Desyree Weakley, RN, Contact Phone Number: 563-324-4384, Sponsor: Boston Scientific Corporation


Spring 2009

Clinical Trials - Continued

- ♥ **POLAR CATHETER:** Reduced Stent Utilization with Cryoplasty Using the Ppar Catheter versus Plain Old Balloon Angioplasty: A Randomized Trial....Principal Investigator: Nicolas W. Shammass, MD, Clinical Coordinator: Denise Coiner, MS, RTR, Contact Phone Number: 563-324-4384, Sponsor: Boston Scientific, Inc.
- ♥ **ROCHE:** A phase III, double-blind, randomized placebo-controlled study, to evaluate the effects of RO4607381 on cardiovascular risk in the stable CHD patients, with a documented recent Acute Coronary Syndrome.....Principal Investigator: Nicolas W. Shammass, MD, Clinical Coordinator: Lori Christensen, RN, Contact Phone Number: 563-324-4384, Sponsor: Hoffmann-La Roche LTD
- ♥ **SAPPHIRE:** SAPPHIRE WW Stenting And Angioplasty With Protection in Patients at High-Risk For Endarterectomy....Principal Investigator: Eric Dippel, MD, Clinical Coordinator: Penny Stoakes, RN, Contact Phone Number: 563-324-4384, Sponsor: Cordis
- ♥ **ST DETECT:** ST Segment Detection Study....Principal Investigator: Blair Foreman, MD, Clinical Coordinator: Lisa Decker, RN, BSN, Contact Phone Number: 563-324-4384, Sponsor: Medtronic
- ♥ **SATURN:** Study of Coronary Atheroma by Intravascular Ultrasound: Effecto of Rosuvastatin Versus AtrovastaiN.....Principal Investigator: Eric Dippel, MD, Clinical Coordinator: Desyree Weakley, RN, Contact Phone Number: 563-324-4384, Sponsor: AstraZeneca
- ♥ **STROLL:** Cordis STROLL Study.....Principal Investigator: Eric Dippel, MD, Clinical Coordinator: Penny Stoakes, RN, Contact Phone Number: 563-324-4384, Sponsor: The Medicine Company
- ♥ **TAMARIS:** A randomized, double-blind placebo controlled parallel group study of the efficacy and safety of 4 administrations of XRP0038/NV1FGF 4mg at 2-week intervals on amputation or any death in critical limb ischemia patients with skin lesions....Principal Investigator: Nicolas W. Shammass, MD, Clinical Coordinator: Lori Christensen, RN, Contact Phone Number: 563-324-4384, Sponsor: Sanofi-Aventis
- ♥ **TRILOGY:** The TRILOGY ACS Study....Principal Investigator: Nicolas W. Shammass, MD, Clinical Coordinator: Lori Christensen, RN, Contact Phone Number: 563-324-4384, Sponsor: Eli Lilly and Company
- ♥ **VIVA II SALVAGE:** (Closed to enrollment.) A ProSepctive, Multi-center TriAL to Evaluate the Safety and Performance of Spectranetics Laser with Adjunct PTA and GORE VIABAHN® Endoprosthesis for the Treatment of SFA Instent Restenosis....Principal Investigator: Eric Dippel, MD, Clinical Coordinator: Penny Stoakes, RN, Contact Phone Number: 563-324-4384, Sponsor: VPI VIVA Physicians Inc.
- ♥ **VIVA I XCELL:** VIVA I: XCELL Trial XPERT™ NITINOL STENTING FOR CRITICALLY ISCHEMIC LOWER LIMBS....Principal Investigator: Eric Dippel, MD, Clinical Coordinator: Penny Stoakes, RN, Contact Phone Number: 563-324-4384, Sponsor: VIVA Physicians, Inc.
- ♥ **ZoMAXX:** (Closed-Currently in follow-up phase.) A Randomized, Controlled Trial to Evaluate the Safety and Efficacy of the ZoMaxx™ Drug Eluting Coronary Stent System as Compared to TAXUS™ Express²™ Paclitaxel-Eluting Stent in *de novo* Coronary Artery Lesions....Principal Investigator: Nicolas W. Shammass, MD, Clinical Coordinator: Denise Coiner, MS, RTR, Contact Phone Number: 563-324-4384, Sponsor: Abbott Vascular Devices
- ♥ **BIVALIRUDIN in PPI:** In hospital outcomes of patients receiving PPI with Bivalirudin: Experience from 2 Medical Centers.....Principal Investigator: Nicolas W. Shammass, MD, Clinical Coordinator: Gail Shammass, RN, Contact Phone Number: 563-324-4384, Sponsor: The Medicine Company



Pictured Below: Eric J. Dippel, MD
President and Associate Research Director
Midwest Cardiovascular Research Foundation



Pictured Above: Nicolas W. Shammass, MD
Founder and Research Director
Midwest Cardiovascular Research Foundation



Cardiovascular Interventions and Practice Guidelines 2009 Conference

The Cardiovascular Interventions and Practice Guidelines (CIPG) 2009 Annual Scientific Sessions will be held at the Adler Health Education Center Genesis Heart Institute, Davenport, Iowa, September 11, 2009.

All registrants will attend the session on Friday, September 11th, with an open buffet lunch for physicians and for allied health care professionals. The session will conclude by 4:00p.m. Log onto our website www.mcrfmd.com for more information.

Cardiovascular Interventions and Practice Guidelines (CIPG 2009) is a multidisciplinary conference for general cardiologists, endovascular specialists, primary care providers, cardiovascular nurses, technicians and nurse practitioners jointly sponsored by Midwest Cardiovascular Research Foundation and the Genesis Medical Center. This symposium is designed to give a comprehensive update in various aspects of cardiovascular diseases and focuses on adhering to national guidelines. The invited faculty will provide attendees with practical tips useful in daily practice.

MCRF Abstracts Presented at the Society for Cardiac Angiography and Intervention Conference

Dr. Nicolas W. Shammass presented the following two (2) abstracts at the Society for Cardiac Angiography and Intervention Conference held on May 6-9, 2009 (in poster format):

Shammass NW, Coiner D, Shammass G, Dippel E, Christensen L, Jerin M. Percutaneous Lower Extremity Arterial Interventions Using Balloon Angioplasty Versus Silverhawk Atherectomy: Results of the SMARTHAWK Randomized Trial. Presented at the Society for Cardiovascular Angiography & Interventions (SCAI) 32nd Annual Scientific Sessions in Las Vegas from May 6-9, 2009



Shammass NW, Shammass G, Coiner D, Dippel E, Christensen L, Jerin M. Walking Impairment Questionnaire, Ankle-Brachial Index and Rutherford-Baker Class in Patients Undergoing Angioplasty Versus Silverhawk Atherectomy: Results from the SMARTHAWK Randomized Trial. Presented at the Society for Cardiovascular Angiography & Interventions (SCAI) 32nd Annual Scientific Sessions in Las Vegas from May 6-9, 2009.

Welcoming Dr. Eric Dippel, MD as President of MCRF

On October 1, 2008, Dr. Dippel became the second president of the Midwest Cardiovascular Research Foundation. Dr. Shammass, Founder and first president (2002-2008) noted that “Dr. Dippel brings with him a wealth of experience in research and education. He had tremendous contribution to the Foundation over the past several years and has been part of its growth since its development. Bringing new leadership into the Foundation is of critical importance to keep its long term viability and inject the foundation with new and exciting ideas”. Dr. Shammass will remain the Research Director and Chief Executive Officer of the Foundation overseeing many of its day-to-day operation and overall research operation. The Foundation has grown from one part time employee to now 8 employees. The Foundation has published 3 books, participated in the writing of several book chapters, published over 60 manuscripts and abstracts and its research has been presented nationally and internationally. In addition, numerous educational programs have been developed including the student research program and the chronic limb ischemia council.



Midwest Cardiovascular Research Foundation was established in 2002 by Nicolas W. Shammass, MD, MS, as a 501(c)(3) non-profit, tax-exempt scientific and educational foundation dedicated to heart health, education and awareness through quality research and professional and community education programs and projects.

Orion Trial

Dr Nicolas W Shammass, MD enrolled the first 2 patients in the USA in the Orion Trial. In this study, the new EPIC nitinol self expanding stent is being tested for the treatment of chronic iliac disease by Boston Scientific. The first 2 patients were enrolled at Trinity Medical Center. The study site is the Midwest Cardiovascular Research Foundation. The Epic stent is placed on a user-friendly delivery device and has edge markers that help in its accurate delivery and improve its visibility.



Pictured Above (from left to right): Niki Lehtinen (Boston Scientific), Dr. Nicolas W. Shammass, MD, Denise Coiner, MS, RTR, Lori Christensen, RN

Recent Publications Carrying MCRF Name

Shammas NW. Optimal Strategy in Lower Extremity Peripheral Percutaneous Interventions: An Interventionalist's Perspective. *Vascular Disease Management* 2009;6:36-40

Shammas NW. Sica DA, Toth PP. A Guide to the Management of Blood Pressure in the Diabetic Hypertensive Patient. *American Journal of Cardiovascular Drugs*, (In print 2009)

Shammas NW. Restenosis in Lower Extremity Interventions: Current Status and Future Directions. *J Endovasc Ther* 2009, 16 (Suppl I): I170-182

Shammas NW. Embolization in lower extremity percutaneous interventions: recommendations and strategies for embolic filter protection use. *Vascular Disease Management*, January/February, 2008;5:22-26

Shammas NW, Shammas GA, Dippel EJ, Jerin M. Intraprocedural Outcomes Following distal Lower Extremity Embolization in Patients Undergoing Peripheral Percutaneous Interventions. *Vascular Disease Management*, 2009; 6(3):1-5

Shammas NW, Dippel EJ, Shammas GA, Farland L, Brosius S, Jerin M, Avila A, Gehbauer L, Winter M, Stoakes P, Byrd J, Sharis P, Robken J. Long Term Outcomes with Bifurcating Coronary Lesions Stenting using the Paclitaxel Drug-Eluting Stent: a Single Center Experience. *International Journal of Angiology*, 2008;17 (2): 88-92

Shammas NW, Coiner D, Shammas G, Dippel E, Christensen L, Jerin M. Percutaneous Lower Extremity Arterial Interventions Using Balloon Angioplasty Versus Silverhawk Atherectomy: Results Of The SMARTHAWK Randomized Trial. Presented at the Society for Cardiovascular Angiography & Interventions (SCAI) 32nd Annual Scientific Sessions in Las Vegas from May 6-9, 2009. *Catheterization and Cardiovascular Interventions*, 2009, 73 (7):S42 (Abstract C-4)

Shammas NW, Shammas G, Coiner D, Dippel E, Christensen L, Jerin M. Walking Impairment Questionnaire, Ankle-Brachial Index And Rutherford-Baker Class In Patients Undergoing Angioplasty Versus Silverhawk Atherectomy: Results From The SMARTHAWK Randomized Trial. Presented at the Society for Cardiovascular Angiography & Interventions (SCAI) 32nd Annual Scientific Sessions in Las Vegas from May 6-9, 2009. *Catheterization and Cardiovascular Interventions*, 2009, 73 (7):S21 (AbstractA-32)

Shammas NW, Dippel EJ, Shammas GA, Jerin M, Bryan D, Rauba J. Does High Sensitivity C-Reactive Protein Predict Target Lesion Revascularization in Patients Undergoing Lower Extremity Percutaneous Interventions? *Transcatheter Cardiovascular Therapeutics* 2008, Washington DC, October 12-17. *American Journal of Cardiology* , 102 (8): 227i, TCT-603

MCRF Board of Directors

Founder and Research Director Nicolas W. Shammass, MD, MS, is an interventional cardiologist with Cardiovascular Medicine, P.C., Davenport, IA, and a Clinical Assistant Professor at the University of Iowa in Iowa City. He founded MCRF in 2002 to facilitate cardiovascular clinical research and education. He has been active as principal or co-investigator in over 100 research trials, has been a participating author in over 130 publications, and is a popular presenter at international professional meetings.

President and Associate Research Director Eric J. Dippel, MD, is an interventional cardiologist with Cardiovascular Medicine, P.C., Davenport, IA. As principal or co-investigator, he is active in peripheral and endovascular research. Dr. Dippel presents his findings through speeches at professional meetings both nationally and internationally, and as an author in industry publications.

Director Clark Arons, CLU, FIC, Bettendorf, IA, is a Senior Financial Consultant with Thrivent Financial for Lutherans, specializing in money management, estate planning and charitable giving. He is active in the community, serves on many boards and is a motivational speaker for young people.

Director John DeDoncker, Bettendorf, IA, is the President of THE National Bank, Bettendorf, IA. As an attorney and banking executive, he shares his expertise on many community organization boards.

Director Blair Foreman, MD, is a cardiologist and electrophysiologist with Cardiovascular Medicine, P.C., Davenport, IA. He actively participates in cardiovascular research projects focusing on electrophysiology.

Director James Kapalis, Bettendorf, IA, is a retired executive of Deere & Company, Moline, IL, and is currently President of Global Supply Chain Solutions, Inc., Bettendorf, IA. He serves as a member of the American Red Cross Disaster Team, and is an active member on many community organization boards.

Director Peter P. Toth, MD, PhD, is the Director of Preventive Cardiology at the Sterling Rock Falls Clinic, in Sterling, IL and editor-in-chief of the *Journal of Applied Research in Clinical and Experimental Therapeutics*. He is active in research and a frequent speaker at national and international professional meetings.

TO CONTACT MCRF.....

Feel free to contact us regarding submitting manuscripts or articles, obtaining publications, booking a speaker, contributing funds or other matters.

To submit manuscripts, discuss research possibilities, etc., contact:

Dr. Nicolas W. Shammass, MD
Founder & Research Director
Editor-in-Chief, Editorial Board
shammass@mchsi.com

For other assistance or information, contact:

Maureen Koepke
Office Manager
563.324.2828
koepkem@mcrfmd.com



We're On The Web!

www.mcrfmd.com

Midwest Cardiovascular Research Foundation

1622 E. Lombard Street
Davenport, IA 52803

Phone: 563.324.2828
Fax: 563.324.2835

MCRF Donation Form

YES, I want to help support Midwest Cardiovascular Research Foundation research projects and education to promote heart health in this community.

First Name

Last Name

Home Phone

E-mail Address

Home Address

City State Zip

- Senior - \$15
- Family - \$25
- Patron - \$100
- Founder - \$500
- Student - \$15
- Sustainer - \$50
- Benefactor - \$250
- Visionary - \$501+
- Individual - \$20
- My employer will match my gift. I enclose the form for the matching gift.

Checks should be payable to Midwest Cardiovascular Research Foundation

GIFTS are a meaningful way to remember someone special. Your gift will be acknowledged by Midwest Cardiovascular Research Foundation to the person/family remembered.

In honor of _____

In memory of _____

Amount enclosed \$ _____

Please send acknowledgement to:

Name

Address

City, State, ZIP



**Midwest Cardiovascular
Research Foundation**

All gifts to MCRF are fully tax deductible under the U.S. Internal Revenue Code.

100% of all gifts are applied to research and education for heart health in this community.

For more information about MCRF visit www.mcrfmd.com or phone 563.324.2828